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Presence of Epstein–Barr Virus in Langerhans Cells
of CTCL Lesions
To the Editor:
The etiology of cutaneous T cell lymphomas (CTCL) remains
unknown, so the involvement of viral agents and among them,
Epstein–Barr virus (EBV), is suspected in the development of
this pathology (Lee et al, 1990; Anagnostopoulos et al, 1996;
Chang et al, 1998). Thus, it has been shown that keratinocytes
of skin lesions of CTCL expressed EBV proteins in the skin of
CTCL patients and that this detection was specific to this
pathology (Dreno et al, 1994). Moreover, a significant increase
of the titer of anti-EBV antibodies, particularly viral capsid
antigen (VCA) antibodies, in CTCL patients compared with
healthy controls, has been demonstrated (Jumbou et al, 1997).
Because of the observations mentioned above, we have
focused on the nature of the EBV-expressing cells in these
CTCL lesions.
Six CTCL patients were included in this study: 5 Sezary
syndromes and 1 Mycosis fungoides stage IIb (Table I). The
study was conducted according to Declaration of Helsinki
Principles and the medical ethical committee of Nantes Uni-
versity Hospital approved all described studies. Patients
gave written informed consent. The diagnosis of CTCL was
confirmed by histology and immunochemistry. Moreover, a
dominant Vb T cell clone was identified both in the blood and
in the skin of CTCL5 (Vb13.6) and CTCL6 (Vb2). All patients
except one were serologically positive for EBV. Six normal
skin samples, six atopic dermatitis inflammatory skin sam-
ples and six squamous cell carcinomas of immunosup-
pressed patients were used as controls. Cutaneous sections
were obtained from paraffin-embedded biopsies from lesio-
nal skin of each patient and immunostained for EBNA2, late
membrane protein (LMP), CD3 (all from DAKO, Trappes,
France), and CD1a (Beckman Coulter, Marseille, France) us-
ing the indirect immunofluorescence technique as previously
described. Moreover, a method combining in situ hybridiza-
tion (ISH) and immunochemistry was performed on the same
CTCL biopsies. The ISH was performed using FITC-conju-
gated EBER-1 or BHLF-1 (BamHI fragment of lower stranded
frame) PNA probes (PNA ISH detection kit, DAKO).
Concurrently, for the two patients with a dominant T cell
clone, the cells were isolated with the antibody reactive with
the TCR-Vb-chain overexpressed (Beckman Coulter), and
sorted according separation procedure from Miltenyi Biotec
(Paris, France). Then total RNA was extracted from Vbþ
clones and non-sorted PBMC using the Trizol chloroform
method, and cDNA was prepared by standard methods
using reverse transcriptase and oligo-dT primer. The reac-
tion cycle consisted of denaturation for 1 min at 941C, an-
nealing for 1 min at 601C for EBV probes, at 551C for b-actin
and then extension for 1 min at 721C, and was repeated 30
times. Positive control was the Akata cell-line, derived from
a Burkitt’s lymphoma patient.
By immunochemistry, EBNA2 protein was identified in
epidermal cells of five of six skin lesions (Fig 1A), whereas
no labelling was obtained in normal control skin, in atopic
dermatitis skin, and in immunosuppressed patients’ skin
(p¼0.02, Fisher exact test, OR (odd ratio) infinite). Non-
involved skin of CTCL patients have also been tested and
we found an expression of EBNA2 in the epidermis as in
lesional skin. No LMP expression was observed in the skin
lesions of six CTCL patients. To identify the phenotype of
EBV-expressing cells in epidermis, a double staining has
been performed showing that only CD1a-positive cells were
EBNA2 positive (Fig 1B and C). The mean percentage of
infected cells (CD1aþ EBNA2þ ) in epidermis among three
fields (  40) examined was 16%  3%. Moreover, the
methodology combining ISH and immunochemistry showed
that CD1a-positive cells were also EBER1 positive (Fig 1D),
but not BHLF positive. There was no difference according
the stage of the illness.
For the two patients with a dominant T cell clone, Vbþ
cells were sorted from blood and an EBV RT-PCR was per-
formed on the extracted RNA. We found no expression of
the EBV genome among neither Vbþ cells, nor non-sorted
PBMC (Fig 1E).
In summary, our study revealed that positive EBNA2 cells
are present in the epidermis of five of six CTCL biopsies,
Table I. Correspondence between number of the patient, cir-
culating Sezary cells, detection of a phenotypic Vb dominant T
cell clone and EBV serology
Patient
Circulating
Sezary
cells (%)
Vb
dominanta
Serology
EBV (IgG,
U per mL)
Stage of
the disease
CTCL1 0 NF 1900 MF IIb
CTCL2 60 NF Neg SS
CTCL3 80 NF 130 SS
CTCL4 56 NF 82 SS
CTCL5 97 Vb13.6 370 SS
CTCL6 75 Vb2 1100 SS
aDetermined by flow cytometry.
EBV, Epstein–Barr virus; CTCL, cutaneous T cell lymphoma; NF, not
found with the panel of antibodies used; MF, mycosis fongoı¨de; SS, Se-
zary syndrome.Abbreviations: CTCL, cutaneous T cell lymphoma; EBV, Epstein–
Barr virus; LC, Langerhans cell
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whatever the stage may be. These EBNA2þ cells appear
specific to CTCL skin lesions because of the lack of EBV
expression in normal skin and in atopic dermatitis. Double
labelling demonstrates that these EBNA2þ cells are
CD1aþ cells, in other words Langerhans cells (LC). More-
over, we show that CD1aþ cells express EBER1 RNA, by a
method combining immunochemistry and ISH, so this de-
tection of EBV RNA within LC implicates a successful in-
fection of LC by EBV.
This EBV infection raises the question of the potentially
modified status of the LC: thereby such modified cells could
attract T lymphocytes in the skin and induce their activation
and chronic proliferation in the skin.
It is well known that the number of LC is elevated in the
epidermis of CTCL (Meissner et al, 1993), decreased when
remission occurs and increased as lesions recur (Braver-
man et al, 1987). The presence of the Pautrier microab-
scess, composed of large cluster of epidermotropic T cells
surrounding LC in the epidermis and in dermal infiltrates
shows that there are tight interactions between these cells
(Chu et al, 1984). Our hypothesis is that due to this close
apposition, the development of CTCL may be driven by LC
triggering off CTCL cells growth through engagement of the
T cell TCR. According to Berger et al, the growth of T
lymphocytes of CTCL would be stimulated by CD1aþ au-
tologous DC (Berger et al, 2002). Indeed, they report that T
lymphocytes of CTCL could be grown in culture for 3
months when co-cultured with immature autologous DC.
The T cell would retain the phenotype of the initial malignant
clone, whereas the APC would be a mixture of immature
and mature DC, the survival of both cell types being de-
pendant on direct membrane contact.
In conclusion, our results show that EBV is absent in T
lymphocytes from the blood of CTCL. But for the first time,
we demonstrate the presence of this virus in the LC of the
epidermis, with an expression of EBER1 RNA and EBNA2
protein. The virus could also play a role either in the mod-
ification of the functionality of these LC and in the activation
and proliferation of T lymphocytes.
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Association of TNF 238 and 308 Promoter Polymorphisms
with Psoriasis Vulgaris and Psoriatic Arthritis but not with
Pustulosis Palmoplantaris
To the Editor:
Overexpression of tumor necrosis factor (TNF)-a is a central
element in the pathogenesis of psoriasis vulgaris (PV) and
psoriatic arthritis (PsA); however, the underlying mecha-
nisms are poorly understood. Several recent studies with
German patients found an association between the rare A
allele of the G ! A single nucleotide polymorphism at po-
sition 238 of the TNFA promoter and psoriasis, particularly
in patients with early disease onset (Arias et al, 1997; Hohler
et al, 1997; Reich et al, 1999; Hohler et al, 2002; Reich et al,
2002). There is also evidence that carriage of the rare A
allele of another G ! A single nucleotide polymorphism at
position 308 of the promoter is decreased in patients with
PsA (Hohler et al, 2002), although within this disease sub-
group it may be increased in patients with a more progres-
sive course of joint involvement (Balding et al, 2003). In light
of the possible influence of TNFA promoter polymorphisms
on cytokine production (Hajeer and Hutchinson, 2001), the
increased formation of TNF-a in psoriasis could at least
partially be genetically determined.
In this study, TNFA 238 and 308 genotypes were
analyzed in 239 unrelated patients with PV, 43 patients with
pustulosis palmoplantaris (PPP) without concomitant PV,
and 135 control subjects according to published methods
(Reich et al, 2002). All participants were Caucasians and
were enrolled at the Department of Dermatology, University
of Tartu, Estonia. Patients with PV were considered to have
early-onset disease if skin symptoms occurred before 40 y
of age, and late-onset disease if age at onset was X40 y
(Henseler and Christophers, 1985). Disease severity was
assessed at study entry by determination of the psoriasis
area and severity index (PASI) (Fredriksson and Pettersson,
1978). PV patients were classified to have concomitant PsA
(n¼59) if this diagnosis had been established by an expe-
rienced rheumatologist. Clinical deformities of the hands
and/or feet consistent with PsA were seen in 23 of these
patients, and nine patients had erosions of the hands and/or
feet by radiographic assessment. Control subjects were
recruited from among medical students, health care per-
sonnel, and patients presenting at the dermatological
outpatient clinic with mild expression of either facial tel-
eangiectasis or skin tags. The study was approved by the
Ethics Review Committee on Human Research of the Uni-
versity of Tartu, and was conducted according to the
Declaration of Helsinki protocols. Informed consent was
obtained from all participants.
To evaluate deviation from the Hardy–Weinberg equilib-
rium, observed and expected genotype frequencies were
compared by a Monte-Carlo goodness-of-fit test in PV and
PPP patients and in controls. Odds ratios (OR) and exact
95% confidence intervals (CI) were calculated to compare
genotype frequencies. Carriage rates of variant allele were
investigated using the exact test by Fisher. To correct for
multiple testing, a hierarchical test strategy was adhered to
as described (Reich et al, 2002), and the respective nominal
p values (pnom) were adjusted according to Bonferroni–
Holm (padj).
Absolute and relative TNFA genotype frequencies are
shown in Table I. The genotypes were in Hardy–Weinberg
equilibrium with the exception of the TNFA 238 locus in
the PPP subgroup (p¼ 0.0118). TNFA genotype frequencies
in the control group were similar to those observed in other
large European studies (Hohler et al, 1997; Reich et al,
2002).
Carriage of TNFA 238A was significantly more com-
mon among patients with PV than among control subjects
(23.8% vs 8.9%; OR 3.21 [1.60–6.84], padj¼0.0012), where-
as carriage of TNFA 308A was decreased (17.6% vs
29.6% in controls, OR 0.51 [0.30–0.86], padj¼0.0360). The
latter finding was independent of TNFA 238 as the differ-
ence between patients and controls remained similar after
exclusion of 238A positive individuals from the analysis
(20.3% vs 30.9% in controls).
Abbreviations: CI, confidence interval; OR, odds ratio; padj, ad-
justed p value; pnom, nominal p value; PASI, psoriasis area and
severity index; PPP, pustulosis palmoplantaris; PsA, psoriatic ar-
thritis; PV, psoriasis vulgaris; TNF, tumor necrosis factor
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